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Neural tube defects (NTDs) are associated with substantial mortality, morbidity, disability, and psychological and
economic costs. Many are preventable with folic acid, and access to appropriate services for those affected can
improve survival and quality of life.We used a compartmentalmodel to estimate global and regional birth prevalence
of NTDs (live births, stillbirths, and elective terminations of pregnancy) and subsequent under-5 mortality. Data
were identified through web-based reviews of birth defect registry databases and systematic literature reviews.
Meta-analyses were undertaken where appropriate. For 2015, our model estimated 260,100 (uncertainty interval
(UI): 213,800–322,000) NTD-affected birth outcomes worldwide (prevalence 18.6 (15.3–23.0)/10,000 live births).
Approximately 50%of cases were elective terminations of pregnancy for fetal anomalies (UI: 59,300 (47,900–74,500))
or stillbirths (57,800 (UI: 35,000–88,600)). Of NTD-affected live births, 117,900 (75%) (UI: 105,500–186,600)
resulted in under-5 deaths. Our systematic review showed a paucity of high-quality data in the regions of the world
with the highest burden. Despite knowledge about prevention, NTDs remain highly prevalent worldwide. Lack of
surveillance and incomplete ascertainment of affected pregnancies make NTDs invisible to policy makers. Improved
surveillance of all adverse outcomes is needed to improve the robustness of total NTDprevalence estimation, evaluate
effectiveness of prevention through folic acid fortification, and improve outcomes through care and rehabilitation.
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Introduction
Neural tube defects (NTDs) are a group of severe
congenital disorders associated with substantial
mortality, morbidity, long-term disability, and
psychological and economic costs.1 Many NTDs
are preventable with folic acid,2–4 and long-term
survival and quality of life among those living with
NTDs can be improved through access to appro-
priate clinical care and rehabilitative services.5–7
However, efforts for primary prevention and
addressing the needs of those living with NTD have
been hampered by a lack of transparent prevalence
estimates to quantify the burden, especially in
resource-poor settings. The Modell Database of
Congenital Disorders (MGDb) was developed
recently to estimate the birth prevalence of congen-
ital disorders globally.8,9 Previous global estimates
using this method were published in the March of
Dimes Global Report on Birth Defects.10 These pro-
vided an estimate of 323,900 live births with NTDs
in 2001; however, neither detailed methodology
nor uncertainty estimates were provided.10 Here,
we build on the Modell methodology to generate
current global and regional prevalence estimates
for NTDs, with uncertainty intervals (UIs), for the
year 2015 using updated input parameters.
Data to inform the prevalence of NTD are
available from a number of sources, including
population- and hospital-based birth defect
surveillance registries; multicenter birth defects
monitoring networks, such as the European
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Surveillance of Congenital Anomalies and Twins
(EUROCAT),11 the International Clearinghouse
for Birth Defects Surveillance and Research
(ICBDSR),12 the Latin American Collaborative
Study of Congenital Malformations (ECLAMC),13
the National Birth Defects Prevention Network
(NBDPN),14 and the World Health Organization
(WHO) South-East Asia Region’s Newborn and
Birth Defects Database (SEAR-NBBD);15 indi-
vidual hospital-based registration systems; and
research studies (including hospital-based studies
and household surveys). There are substantial
differences in prevalence estimates based on sources
of data and surveillance methodology. Ideally, a
population-based surveillance system with clear
case definitions and a defined geographical catch-
ment area and including all pregnancy outcomes
would yield the most complete estimate of NTD
prevalence. However, such systems are lacking in
all countries, with even the most comprehensive
systems failing to capture spontaneous miscarriages
and early fetal losses, where detailed investigation
is rarely undertaken. Thus, we consider only
measurable birth outcomes (live births, stillbirths,
and elective terminations of pregnancy for NTDs).
The accuracy of surveillance methods can have
significant effects on prevalence. Systems that
include prenatal ascertainment and survey multi-
ple data sources for documentation and triangula-
tion of birth defects identify a greater number of
cases compared with systems that track live births
alone and rely on a single data source.16 Incorrect
documentation of birth outcomes and diagnosis
of birth defects result in misclassifications between
stillbirths and live births and isolated versus multi-
ple defects (especially in stillbirths or early neona-
tal deaths without autopsies). Prevalence is largely
under-ascertained and is highly variable, particu-
larly in low- andmiddle-income countries (LMICs)
without a capacity to use multiple data sources and
limited tracking of elective termination of preg-
nancy for fetal impairment (eTOPFA) and stillbirths
due to legislative or cultural barriers.
Apart from methodological influences, the esti-
matedprevalenceofNTDscanbe influenced inpop-
ulations by underlying risks due to genetic (such
as MTHFR mutations among women of specific
race and ethnicity), environmental, and nutrition
differences,17–19 as well as factors such as access to
diagnostic services.20
To date, there has not been a standard approach
for estimating NTD prevalence and presenting
global and regional estimates. Different studies and
registries use different approaches. The numera-
tors in prevalence estimation generally include live
births, and where possible stillbirths and eTOP-
FAs. Fordenominators, themost commonapproach
is to use live births, with some countries includ-
ing stillbirths where data are available. The correct
denominator would include live births, stillbirths,
and eTOPFAs; however, the overall frequency of
stillbirths and eTOPFAs in the population is rela-
tively small compared with overall live births, and
their omissionwill haveminimal effect on thepreva-
lence estimate. As neither estimates of prevalence of
eTOPFA or stillbirths 20 weeks are available for
themajority of countries, using an approach similar
to that taken for maternal mortality,21 we included
only live births in the denominator.
Here, we describe available data and generate
regional and global estimates of the prevalence of
NTD-affectedbirthoutcomes andassociatedunder-
5 mortality for the year 2015. The prevalence esti-
mates include only observed NTD birth outcomes,
including live births, stillbirths, and eTOPFAs.Chal-
lenges in tracking pregnancies and the consequent
paucity of datamake it impossible to estimateNTD-
associated early fetal losses and miscarriages. These
estimates therefore represent an underestimate of
the total number of NTD-affected pregnancies.
Methods
We sought to include as many available data sources
as possible: (1) birth defect registries and (2)
published literature. We undertook premodeling
adjustments where necessary, seeking to improve
data comparability between countries. The esti-
mates are reported using the Guidelines for Accu-
rate and Transparent Health Estimates Reporting
(GATHER)22 (see Appendix S1, online only).
Case definition
NTD-affected pregnancy is a pregnancy where the
fetus is affected by one or more of the three major
subgroups of NTDs: anencephaly, spina bifida, or
encephalocele. NTD-affected pregnancies can result
inoneof fouroutcomes: (1) anearly fetal loss ormis-
carriage (defined as a spontaneous pregnancy loss at
<20 completed weeks of gestation), (2) a fetal death
or stillbirth (a spontaneous pregnancy loss at 20
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Figure 1. Overview of interventions for and outcomes of neural tube defect–affected pregnancies. Adapted fromBlencowe, et al.28
1Including maximizing the control and appropriate medications for chronic conditions, including epilepsy and diabetes, with
preconception optimization of medication to reduce risk. 2Including information on eTOPFAs where they are legal and where it
is the parental choice, prognosis and long-term outcomes, and plans for delivery. 3Including delivery in a hospital with neonatal
intensive care/neonatal surgical capabilities, planned cesarean section if required.
completed weeks of gestation), (3) eTOPFA, or (4)
an affected live birth. Figure 1 presents an overview
of the possible outcomes of NTD-affected pregnan-
cies and the interventions that can affect both the
prevalence and the outcomes of these conditions.
For this analysis, we considered in the numerator
all NTD-affected pregnancy outcomes at20 com-
pleted weeks of gestation and eTOPFAs at any gesta-
tion. Estimates of NTD-affected early fetal losses are
not clearly possible. Data were also analyzed for the
three major subgroups of NTDs. The term “birth
outcomes” is used to refer to live births, stillbirths at
20 completed weeks of gestation, and elective ter-
minations of pregnancy for NTDs at any gestation.
Prevalence data search: methodology
Birth defect registries. A web-based review of all
available birth defect registry databases and multi-
center birth defects monitoring networks (includ-
ing EUROCAT, ICBDSR, ECLAMC, NBDPN, and
SEAR-NBBD) was undertaken inMarch 2017. Data
from all available registries for all years since 2000
were abstracted from each data source onto a stan-
dard abstraction form. Data were available for all
years frommostof these sources; therefore, to ensure
that only the most recent data were used to inform
the 2015 estimate, only data from 2005 onward
were included (Appendix S2, online only). Country-
specific data were included if they reported at least
live birth and stillbirth outcomes for at least one
subgroup of NTDs for at least a consecutive 5-year
period since 2005. Inconsistent data or data with
more than 50% of values missing were excluded.
Published literature review. To inform estimates
for countries outside high-income country regions
without recent, reliable, and population-based birth
defect registry data on NTD birth prevalence, a
literature review of published studies was under-
taken. The review sought to include publications
with data collection after 2000. Three recent system-
atic reviews summarized the available data on birth
prevalence of one or more subgroups of NTDs in
LMICs (Table 1).23–25 Though each of these applied
different inclusion criteria, overall they provided a
comprehensive review of the literature, and it was
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Table 1. Previous systematic reviews of birth prevalence of neural tube defects
Reference Title Inclusion criteria Search dates
Lo et al.23 Estimating the burden
of NTDs in LMICs
Population- or hospital-based studies reporting
the prevalence of NTDs in LMIC context.
January
2000–February
2013
Zaganjor et al.24 Describing the
prevalence of NTDs
worldwide
Case–control and cross-sectional studies and
reports with either a reported prevalence of
NTDs (anencephaly/spina
bifida/encephalocele) or numerator and
denominator data allowing it to be calculated.
Population5000. Data collection 1990 or
later. Excluded studies only reporting
anencephaly and/or encephaloceles or using
other NTD definitions; data from populations
following a contamination event, case reports,
and supplementation trials.
January 1990–July
2014
Atta et al.25 Global birth
prevalence of spina
bifida by folic acid
fortification status
Original research with data collection since 1985.
Population-based only (all cases in a defined
geographic area or ascertainment from
multiple hospitals or the only hospital in a
defined area). Reported an incidence or
prevalence estimate or cases of spina bifida per
population denominator.
January 1985–
December 2010
NTDs, neural tube defects; LMICs, low- and middle-income countries.
assumed that these search strategies captured all
relevant published studies relating to NTD preva-
lence in LMICs. All studies included in these three
reviews were screened for eligibility. In addition, an
updated systematic review was undertaken cover-
ing January 1, 2013–March 17, 2017 to identify new
publications appearing after the dates of the afore-
mentioned systematic reviews. These searches were
undertaken using the PubMed, Medline, EMBASE,
and Global Health Library databases. Search terms
used included “neural tube defects,” “prevalence,”
and “developing countries” (including individual
LMIC names) (Appendix S3, online only). Full-text
review of the reference lists of all studies was under-
taken to identify any further potential studies with
NTD birth prevalence data.
The systematic review for current analysis
included (1) studies reporting on primary data with
population-based surveillance designs; (2) hospital-
based surveillance studies with a defined geograph-
ical catchment area; and (3) hospital-based studies
reporting birth prevalence of NTD cases after year
2000. Sources reporting a birth prevalence of at least
one subgroupofNTDamongat least oneof thebirth
outcomes or providing a numerator and denomina-
tor to allow the calculation of the birth prevalence
were included. Studies not meeting inclusion cri-
teria, duplicate studies, and studies from countries
with alternative reliable population-based birth reg-
istry data were excluded from the systematic review
(Appendix S3, online only).26 A checklist validated
by Hoy et al. was adapted to assess study quality.
Data from referral hospitals including pre- or post-
natally referred cases were excluded (Appendix S3,
online only).
Prevalence data search: results
Birth defect registries. The web-based review of
birth defect registry data retrieved recentNTDbirth
prevalence data from 44 countries. Birth defect reg-
istry data from 39 countries met inclusion criteria
and were included in the input database and con-
tributed to the regional meta-analyses as appropri-
ate. Birth defect registry data from four countries
were excluded. These included Ireland, where more
complete data from the registry were published;27
New Zealand and the Slovak Republic, where only
data on NTD-affected live births were available;12
and Iran, owing to substantial data quality con-
cerns and missing outcomes for multiple years.12
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For the United States, where data were available for
stateswith andwithoutprenatal ascertainment, only
data from states with prenatal ascertainment were
included, as the latter have lower reported preva-
lence, which is likely to be attributable to lower case
ascertainment andmissing eTOPFA outcomes.16 As
NTDs are a relatively rare outcome, and hence sub-
ject to year-to-year variation in prevalence, pooled
prevalence data across available years from 2005 to
2015 were used as inputs to the database. Data from
23 countries identified through these searches plus
comprehensive published data from Ireland27 were
assessed as subject to minimal biases and likely to
provide a representative estimate ofNTDprevalence
in the country. See Appendix S2 for further details
and Appendix S3 for list of included data (online
only).
Published literaturereview. The literature review
retrieved a total of 654 published study titles. Of
these, 128 studies were considered for analysis
after removing duplicates, studies not relevant to
NTD prevalence, and data from countries with reli-
able birth registry data. A further 98 studies were
excluded on full text review, and seven studies added
from the reference lists searches. In total, 37 stud-
ies from 23 countries were included in the input
database (Appendix S3, online only).
Estimation of access to services
For countries without data, the proportion of
women and infants with access to a comprehensive
package of optimal services, including diagnostic
and specialist services such as urology and padiatric
surgery,was estimatedusing an approachpreviously
developed for the Modell Global Database where
access to services is estimated based on the current
infant mortality rate (Appendix S4, online only).8,28
As eTOPFAs for NTDs are affected not only by the
availability of prenatal diagnosis by prenatal ultra-
sound scan but also by the legal status, national
policy, and local clinical and cultural practices of
eTOPFA in each country, an adapted approach was
undertaken (Appendix S5, online only).28,29 For
countries with no observational data, we assumed
that the comprehensive package of optimal ser-
vices includes routine antenatal ultrasound screen-
ing for structural abnormalities. In countries for
which birth registry data on eTOPFAs are available,
reported rates are used. Where no data are available
and eTOPFA is legal, we assume that the proportion
of women identified through ultrasound screen-
ing opting for pregnancy termination will be the
same as the average rates among women in Europe
(Appendix S6, Table S6B, online only). In coun-
tries where eTOPFA is not legal, unless there is clear
evidence of widespread practice of eTOPFA, it is
assumed for the purpose ofmodeling that no eTOP-
FAs are undertaken (Appendix S5, online only).
Modeling approach
NTD birth prevalence was estimated using a com-
partmental model including four steps: (1) estima-
tion of the overall envelope of prevalence of NTDs
per 10,000 live births; (2) estimation of the preva-
lence of the three subgroups of NTDs per 10,000
live births; (3) estimation of the prevalence of each
birthoutcomebyoverallNTDs andby the three sub-
groups per 10,000 live births, and (4) estimation of
under-5 child mortality from NTDs. All estimates
were generated at a national level by applying the
four steps of the compartmental model in sequence
to the UN Population Division estimated live births
to generate estimated numbers affected for the year
2015.30 All results are presented at the regional
level using the UN Sustainable Development Goals
regional classification31 and at the global level.
NTD prevalence was calculated as:
NTD birth prevalence
= affected live births + affected still births + eTOPFAs for NTDs
live births
×10,000
Premodeling adjustments
Some of the limitations of the available data
include the lack of representativeness, differing
surveillance methods, differing application of case
definitions and classifications, and missing data
for NTD subgroups or outcomes. All of these
can affect case ascertainment and reported NTD
prevalence. Although it is not possible to adjust for
all data limitations, input data were adjusted before
use for missing NTD subgroup, missing birth
outcomes, and reporting of cases versus affected
fetuses/infants, in order to increase comparability.
Overall, 29 of the 76 data inputs (39 from birth
registries and 37 from literature searches) required
some premodeling adjustment (see Appendix S4
for full details of these adjustments, online only).
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Meta-analysis of reported prevalence by
region
Standard meta-analysis techniques with random
effects were used to obtain summary estimates
of the parameters and 95% confidence intervals
where appropriate, including reported prevalence
by region and under-5 case fatality rates (CFRs).
Uncertainty estimation
For NTD birth prevalence, uncertainty was esti-
mated assuming a Poisson distribution. We esti-
mated 95%uncertainty estimates for the proportion
in each NTD subgroup or with each birth outcome
assuming a binomial distribution.
For each step, uncertainty around the estimates
was quantified by taking 1000 random draws of the
input parameters assuming the Poisson or binomial
distributions as above. Data were summed at the
regional or global level for each draw, and the 2.5th
and 97.5th percentiles of the resulting distributions
were presented as the uncertainty range. No esti-
mations of the uncertainty around the estimated
number of live births or access to care assumptions
were included.
All analyses were undertaken in Stata 14. All
data inputs, statistical code, and results are avail-
able online (https://doi.org/10.17037/DATA.264).
Results
Step 1: estimation of the overall envelop of
prevalence of NTDs per 10,000 live births
For countries with recent registry data meeting
inclusion criteria (n = 24). Recent population-
basedbirth registry data thatmet the inclusion crite-
ria, with reported rates that were subject tominimal
biases and likely to provide a representative esti-
mate of NTD prevalence in the country, were avail-
able for 24 countries (Appendix S2, online only).
These regional ornational reportedNTDprevalence
estimates were deemed as the preferred input data
to estimate rates. For countries with only regional
and not national birth defect registry data, reported
regional NTD prevalences were assumed to be rep-
resentative of the whole country. Where more than
one regional registry was available, data pooled at
the country level were used as an input. Only data
from Canada were adjusted to include estimated
eTOPFA; all other data were used as reported.
For countries without recent registry data meet-
ing inclusion criteria (n= 171). NTD prevalence
was estimated based on a meta-analysis of avail-
able regional datameeting inclusion criteria. United
Nations (UN) regions were pooled to create 10
regions (Table 2, Appendix S7, online only). Meta-
analyses were undertaken separately for countries
with and without widespread coverage of a manda-
tory folic acid fortification program, where appro-
priate. Widespread coverage was defined as over
70% of the rice or wheat/maize flour in the coun-
try being fortified, based on data compiled by the
Food Fortification Initiative.32 Meta-analyses were
not undertakenby individual country, as no country
had a large number of input data points.
Step 2: estimation of the prevalence of the
three subgroups of NTDs per 10,000 live
births
Twenty-three of the 24 countries with available
recent birth registry data meeting our inclusion cri-
teria had data on the proportion of NTDs in each
subgroup. For these countries, the proportion of
total NTD-affected pregnancies in each subgroup
was used as reported.
For all other countries, the overall NTD bur-
den was divided assuming the proportion of all
NTDs with each subgroup diagnosis to be equal
to the EUROCAT pooled rates (i.e., when not
tracked, 38.7% of all three major NTD subgroups
was assumed to be anencephaly, 49.2% spina bifida,
and 12.1% encephalocele (Appendix S6, Table S6A,
online only)).11
Step 3: estimation of the prevalence of each
birth outcome by overall NTDs and by the
three subgroups per 10,000 live births
Twenty-three of the 24 countries with recent birth
registry data that met inclusion criteria reported
each birth outcome in each subgroup. For these 23
countries, the reported prevalence and proportions
in each subgroup for each outcome were applied to
the estimated number of live births in that country
in 201530 to produce prevalence estimates for the
year 2015.
For all other countries, the proportion of each
subgroup with a given outcome was estimated as
follows. For populations where eTOPFA is legal or
where there is evidence of widespread practice, we
used EUROCAT pooled data to estimate outcomes
for those with access to specialist services (Table 3,
Appendix S6, Tables S6B and S6C, online only).11
For populations where eTOPFA is not legal, we used
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Table 2. Regional meta-analysis of overall birth prevalence of neural tube defects
Region
Number of
studies
Overall NTD birth prevalence per
10,000 live births
95% Confidence
intervals
Australasia 1 12.10 10.45–13.94
Latin America and the Caribbean: with folic acid
fortification
12 7.78 6.58–8.97
Latin America and the Caribbean: without folic acid
fortification
1 22.89 18.01–28.69
Eastern Europe and Central Asia 6 9.92 7.6–12.24
Sub-Saharan Africa: with folic acid fortificationa 1 9.95 7.26–13.30
Sub-Saharan Africa: without folic acid fortification 6 15.27 10.19–20.34
East Asia 9 19.44 15.46–23.41
Northern Africa and Western Asiab 9 17.45 13.56–21.34
Europe 17 8.63 6.80–10.47
Southeast Asiac 2 6.76 5.77–7.75
North America NA Both countries in region have data
Southern Asiad 11 31.96 23.81–40.12
aBased on a single South African study.1
bStudies are highly heterogeneous. Pooled regional data regardless of folic fortification (see Appendix S6, online only).
cLikely underestimate: used pooled hospital-based data from SEARO Newborn and Birth Defects Database in estimates.2
dIran is the only country in the region with high coverage of folic fortification; we assumed that South Africa postfortification rates
apply.1
contemporary data from Ireland27 for those with
access to specialist services and historical data from
the United Kingdom for those without access to
specialist services (Table 3, Appendix S6, Table S6D,
online only).33–36
The number of NTD-affected live births in each
subgroup was estimated by subtracting the eTOPFA
and stillbirths from the overall estimated NTD-
affected pregnancies in each subgroup. The over-
all NTD birth outcomes were calculated as the sum
of each relevant outcome for each subgroup (e.g.,
total NTD eTOPFA= (eTOPFA for anencephaly)+
(eTOPFA for encephalocele) + (eTOPFA for spina
bifida)). Overall NTD prevalence by outcome was
estimated as thenumber of the subgroupNTDswith
the relevant birth outcome divided by the number
of live births in the population.
Step 4: estimation of under-5 child mortality
from NTDs
The number of under-5 deaths in children with
NTDs was estimated by applying under-5 CFRs
to the estimated live births with NTDs by coun-
try. CFRs, by subgroup, were estimated separately
for children with access to optimal care services
in a lower mortality setting (background neona-
tal mortality rate (NMR) <10), with access to care
services in a higher mortality setting (background
NMR10), or with no access to care or supportive
care only. Supportive care was defined as no avail-
ability of surgical care and includes nursing care and
antibiotics only.
A systematic review of the outcomes of NTDs
to age 5 was undertaken. For anencephaly, all data
sources in all settings confirmed a 100% CFR by
age 1 month. For spina bifida and encephalocele,
there was a paucity of data to inform case fatality
parameters fromall settings.On thebasis of thefind-
ings of the review, the parameters shown in Table 4
were included in the model as the best estimate of
CFRby subgroupunder the three different scenarios
(Table 4). See Appendix S8 (online only) for further
details.
Overall summary of NTD prevalence and
under-5 mortality
Overall, there were an estimated 260,100 (95% UI:
213,800–322,000) NTD-affected birth outcomes
worldwide in 2015, excluding early spontaneous
fetal losses, with a global prevalence of 18.6 per
10,000 live births (95%UI: 15.3–23.0 per 10,000 live
births) (Table 5; Figs. 2 and 3). Of that total, 23%
(59,300 (95% UI 47,900–74,500)) were estimated
to be eTOPFA for NTDs. A similar number of
NTD-affected pregnancies were estimated to result
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Table 3. Percentage of birth outcome parameters used in the compartmental model
NTD subgroup
% Affected pregnancies resulting in
eTOPFAa
% Stillbirths in continuing
pregnancies: no access to
eTOPFA
% Stillbirths in continuing
pregnancies: with access to
eTOPFA
Anencephaly 90.6% of those with access to eTOPFA 56.0% 56.0%
Encephalocoele 61.7% of those with access to eTOPFA 11.3% if NMR< 10
21.8% if NMR 10
3.6%
Spina bifida 73.8% of those with access to eTOPFA 11.3% if NMR< 10
21.8% if NMR 10
3.1%
eTOPFA, elective termination of pregnancy for fetal impairment; NMR, neonatal mortality rate.
aOnly estimated if eTOPFA is legal or there is evidence of widespread practice (Appendix S5, online only).
in stillbirth (57,800 (95% UI: 35,000–88,600)).
Asia and Africa had the highest prevalence of
NTD-associated stillbirths, amounting to 85% of
all NTD-associated stillbirths occurring globally. Of
the estimated 143,200 (95% UI: 105,500–186,600)
NTD-affected live births worldwide in 2015, around
80% (117,900 (95% UI: 81,100–148,500)) were
estimated to die before reaching the age of 5 years,
the majority of these in LMICs (Table 6).
Of the total estimated NTD-affected birth out-
comes in 2015, nearly half (128,000 (95% UI:
98,100–165,600))were estimated tobe cases of spina
bifida (Appendix S9, Table 9A, online only). The
majority of spina bifida–affected birth outcomes
worldwide were estimated to result in affected live-
born infants. In 2015, an estimated 66,000 (95%UI:
45,900–85,000) under-5 child deaths were associ-
ated with spina bifida.
Encephalocele was less common, with an esti-
mated 31,700 (95% UI: 24,700–41,600) affected
birth outcomes worldwide in 2015 (Appendix S9,
Table S9B, online only).
There were an estimated 100,600 (95% UI:
72,000–142,400) anencephaly-affected birth out-
comes in 2015 (Table S8C). In just under a third
of these (27,900 (95% UI: 19,900–40,100)), it is
estimated that the pregnancy was terminated fol-
lowing prenatal diagnosis. The remainder of cases
were estimated to result in stillbirth (36,800 (95%
UI: 15,300–66,600)) or neonatal death soon after
birth (35,800 (95% UI: 14,500–64,700)).
Discussion
In spite of knowledge of the role of folic acid in
the prevention of NTDs for the last 30 years, NTDs
are still highly prevalent worldwide in 2015, with an
approximate 260,000 affected pregnancies, exclud-
ing early spontaneous fetal losses. The majority of
these are preventable cases, and understanding the
current burden can have an important impact on
their prevention. In 2015, there were an estimated
117,900 NTD-associated under-5 deaths. Neona-
tal death is universal for those with anencephaly,
regardless of the setting, and mortality for other
NTDs remains high in many LMIC settings, even
when there is access to care services.37 A simi-
lar number of NTD-affected pregnancies (117,100)
ended in stillbirth or eTOPFA. These women and
their families are frequently faced with stigma, iso-
lation, guilt, and grief, which are often hidden.38
Despite improved outcomes with surgical and
supportive care in high-income countries, affected
individuals have an elevated mortality risk and
residual disabilities and morbidities compared with
unaffected individuals, leading to high levels of
healthcare requirements. The economic, social, and
psychological costs of caring for the needs of an
affected child are large.39–41 For the affected indi-
vidual, the consequences are lifelong and frequently
under-recognized.42–44 Most LMICs do not have
adequate healthcare professionals or services to
address the surgical and multidisciplinary needs of
those born with NTDs.
For society, NTD-affected pregnancies incur high
costs, in terms of both direct expenditure on health-
care forwomen and affected individuals and societal
costs in termsof lost human capital.45 These impacts
can be mitigated, at least in part, and quantification
of the estimated prevalence and associated under-5
mortality canbring this issue, previously often invis-
ible, to the attention of policy makers to facilitate
improved resources to address the issue, as has been
seen with other recent global estimates.46 Increas-
ing investment in both public health and patient
services can improve outcomes.
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Table 4. Percentage of under-5 mortality parameters used in the compartmental model
NTD subgroup
No care/supportive care only
(uncertainty range)
Optimal care including surgery
background NMR10
(uncertainty range)
Optimal care including surgery
background NMR<10
(uncertainty range)
Anencephaly 100% 100% 100%
Spina bifida 95% (90–100%) 46.7% (38.4–55.1%) 18.3% (11.5–25.1%)
Encephalocoele 95% (90–100%) 46.7% (38.4–55.1%) 27.9% (24.4–31.9%)
NMR, neonatal mortality rate.
First, many NTDs are preventable with improved
maternal folate status. Although adequate intake of
folic acid does not prevent 100% of cases, owing to
other environmental and genetic factors that influ-
ence the risk of NTDs, studies have shown it to
be an effective preventative strategy.2 While there
is strong evidence to support a positive effect of
mandatory folic acid fortification on NTDs,4,16,47
evidence suggests that folic acid supplementation is
usually commenced too late, and voluntary fortifi-
cation has little impact.20,48 Advocacy and resources
are required for more folate-sensitive NTDs to be
prevented through universal food fortification, and
also through targeting women at high risk, includ-
ing those with a previous NTD-affected pregnancy
or chronic conditions (e.g., epilepsy), to optimize
prepregnancy folate status.49
Second, access to adequate health care, support-
ive care, rehabilitation, and educational services can
improve outcomes. These include access to prenatal
diagnosis and information to allow women and
families, together with health professionals, to plan
optimal care within the appropriate legal, cultural,
and belief systems. These may include eTOPFA
or planned timing and place of delivery and
ongoing support for affected women and families,
particularly after a pregnancy loss or bereavement.
Postnatal services, including surgical services and
ongoing urological, rehabilitation, education, and
supportive services, can improve the quality of life
for affected individuals and their families. In many
settings, the comprehensive, multidisciplinary,
intersectoral team required to provide this is
frequently lacking. In LMICs, even when surgical
services are present, substantial barriers limit their
uptake; in one study in Zambia, these included
geography, economics, transportation, attitudes of
healthcare workers, and beliefs of the women.50
The long-term prognosis and quality of life of the
20,900 survivors with spina bifida and 4300 with
encephalocele to age 5 could be improved with bet-
ter access to full supportive and rehabilitative care.
Limitations
A large limitation of this work is the paucity of high-
quality surveillance or observational data, especially
fromLMICs,which have the highest burden ofNTD
as a function of maternal malnutrition. We made
numerous assumptions to arrive at our modeled
estimates. To improve data comparability, premod-
eling adjustments of the input data were undertaken
where possible. However, not all data limitations
could be addressed.
Many previous studies seeking to quantify NTD
burden in specific settings have excluded eTOPFA
and/or stillbirths from their analyses, and hence
substantially underestimate the total burden. While
we sought to estimate all NTD-affected pregnancies
resulting in a live birth, fetal death at 20 weeks of
gestation, or eTOPFA for NTDs regardless of gesta-
tional age, it was not possible to include estimates
of early fetal losses/miscarriage due to paucity of
data. These estimates therefore represent an under-
estimate of the total number of NTD-affected preg-
nancies.
For our analysis, the term “stillbirth” was used to
describe all fetal deaths, regardless of the definition
used. Where possible, consistent with the majority
of birth defect registries, fetal deaths at 20 weeks
of gestation were used. Older data sources and those
fromLMICs tended to use the28weeks definition;
however, this is unlikely to have a major effect on
the estimate, since the majority of NTD-affected
stillbirths occur during the third trimester.
Where possible, we sought to use national or
nationally representative population-based data;
however, this was available for only a minority
of countries. For countries with population-based
surveillance data available at a subnational level
only, we assumed that these data would be a better
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Table 5. Estimated overall neural tube defect birth outcomes worldwide in 2015
UN subregion
Regional
average
prevalence
per 10,000
live births
(UR)
Number of
NTD-affected birth
outcomes (UR)
Regional
average
eTOPFAs for
NTD
prevalence
per 10,000
live births
(UR)
Number of
eTOPFAs for
NTDs (UR)
Regional
average
stillbirth
prevalence
per 10,000
live births
(UR)
Number of
NTD-related
stillbirths (UR)
Regional
average NTD
live births per
10,000 live
births (UR)
Number of
NTD-affected live
births (UR)
Australasia and
Oceania
12.1
(8.5–15.7)
750
(530–980)
5.6
(4.7–6.4)
350
(290–400)
1.6
(0.7–2.8)
100
(40–180)
4.9
(2.7–7.2)
300
(170–450)
Latin America and the
Caribbean
8.6
(3.6–13.7)
9500
(3900–15,000)
2.9
(1.2–5.1)
3200
(1300–5600)
0.7
(0.2–1.4)
790
(250–15,200)
5.0
(2.1–7.2)
5500
(2300–7900)
Eastern Europe and
Central Asia
9.7
(6.6–12.9)
4800
(3300–6400)
5.5
(4.1–7.0)
2700
(2000–3500)
0.8
(0.4–1.6)
440
(190–780)
3.3
(2.0–4.7
1600
(1000–2400)
Sub-Saharan Africa 14.2
(8.0–24.0)
49,100
(27,700–83,100)
0.4
(0.2–0.6)
1300
(700–2200)
4.5
(2.2–8.3)
15,400
(700–28,700)
9.3
(5.0–16.0)
32,300
(17,400–55,300)
East Asia 19.4
(11.0–28.0)
36,800
(20,800–53,100)
14.3
(8.0–20.7)
27,000
(15,100–39,300)
0.6
(0.3–1.1)
1200
(500–2100)
4.6
(2.5–7.0)
8700
(4800–13,200)
Northern Africa and
Western Asia
17.5
(9.8–25.6)
20,700
(11,600–30,400)
4.8
(2.5–6.9)
5700
(3000–8100)
2.8
(1.4–4.7)
3300
(1600–5500)
9.8
(5.9–14.9)
11,700
(7000–17,700)
Europe 9.6
(8.8–10.4)
4200
(3900–4600)
7.3
(6.7–7.9)
3200
(3000–3500)
0.2
(0.1–0.3)
90
(50–140)
2.0
(1.9–2.3)
910
(830–1020)
Southeast Asia 13.1
(6.0–20.0)
16,100
(7400–24,500)
1.4
(0.6–2.1)
1700
(800–2600)
2.7
(1.1–4.7)
3300
(1400–5800)
9.1
(4.3–14.0)
11,100
(5300–17,200)
North America 7.5
(7.1–7.8)
3100
(2900–3300)
5.3
(5.0–5.6)
2200
(2100–2300)
0.3
(0.1–0.4)
(60–150) 2.1
(1.9–2.2)
860
(900–920)
Southern Asia 31.2
(22.0–43.0)
115,000
(81,200–158,800)
3.2
(2.6–5.0)
11,800
(9500–18,600)
9.0
(4.9–14.3)
33,100
(18,200–52,700)
19.0
(12.5–27.1)
70,200
(46,200–100,000)
Worldwide 18.6
(15.3–23.0)
260,100
(213,800–322,000)
4.2
(3.4–5.3)
59,300
(47,900–74,500)
4.1
(2.5–6.3)
57,800
(35,000–88,600)
10.2
(7.5–13.4)
143,200
(105,500–186,600)
eTOPFA, elective termination of pregnancy for fetal impairment; UR, uncertainty range.
Note: Numbers may not add up because of rounding. Numbers in each cell are rounded to the nearest 10 for numbers <1000 and
the nearest 100 for numbers1000.
representation of the overall country rate than a
pooled regional estimate. However, some coun-
tries have highly variable regional prevalence rates,
reflecting variation in folate status of women.51 For
countries and regions without national or nation-
ally representative high-quality population-based
data, we included data from hospital-based surveil-
lance systems. Hospital-based data may underesti-
mate prevalence in settings where only the wealthy
are able to access facility-based care or where regis-
tration is voluntary and overestimate prevalence in
settings where data come from the tertiary hospital
where all cases are referred. All studies assessed had
amoderate-to-high risk of bias, particularly regard-
ing their generalizability to the national population.
We sought tominimize overestimation by excluding
data including prenatally and postnatally referred
cases from the literature review. This assessmentwas
more challenging in the hospital-based registry data
sourceswheredetaileddescriptionwas less available.
Region-specific data were lacking from the South-
East Asia region. For this region, we used initial
data based on the newly established hospital-based
SEAR-NBDD database. This represents an impor-
tant step toward counting perinatal conditions and
birth defects in the region. As further data collec-
tion is undertaken in the region, a full assessment of
the validity and reliability, including case ascertain-
ment and misclassification, should be undertaken,
and future estimates updated accordingly.
The analysis sought to include an estimate of the
number of eTOPFAs due to NTDs in 2015. In view
of the limitations of the data highlighted above, sev-
eral assumptions were required in this estimation.
For countries with no observational data, we first
estimated the proportion of the population with
access tooptimal specialist services, including timely
antenatal ultrasound screening for structural abnor-
malities. In the absence of empirical data, this is
based upon the assumptions detailed above. It is
assumed that no eTOPFAs are undertaken where
eTOPFA is illegal, unless documented evidence of
widespread practice is available. However, it is pos-
sible that women may be accessing these services,
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Figure 2. Regional stacked bar chart showing the estimated number of NTD-affected birth outcomes.
but no formal documentation is available; hence,
eTOPFAswouldbeunderestimated in these settings.
For countries with no observational data and where
eTOPFA is legal or its use iswidespread, it is assumed
that women will terminate affected pregnancies at
the EUROCAT average rates. This may overesti-
mate eTOPFAs for spina bifida in some regions,
especially where the quality of ultrasound diagno-
sis is less robust, leading to fewer cases detected,
or where eTOPFA, though legal, is less culturally
accepted, or where geographical, financial, or other
barriers limit access. Overestimation of eTOPFAs
in these settings would not affect the overall esti-
mated burden but would lead to underestimates
of affected stillbirths, live births, affected individ-
uals living with disability, and child deaths. Con-
versely, the assumption that no eTOPFA occurs in
countries where eTOPFA is not legal is likely to
underestimate eTOPFAs in those countries. In set-
tings where termination of pregnancy is not legal,
many women undergo illegal, unsafe abortions.52
As routine prenatal ultrasound scanning becomes
more widespread, more women with affected preg-
nancies may seek eTOPFA, regardless of its legal
status.
Where data regarding the split by subgroup
of NTDs were not available, we assumed that
the EUROCAT average rates would apply. This
approach was taken, as EUROCAT provides the
most robust population-based data available. How-
ever, it has some limitations in that the distribution
of the subgroups may vary according to nutritional,
genetic, or other factors. Limited data are available
to adequately quantify these differences, with a
lack of high-quality population-based data with a
low risk of bias from regions likely to differ most
from Europe in terms of nutrition and genetic
factors. Of the 37 included studies from low- or
middle-income settings, only six populations from
five studies presented data on the distribution
of the subgroup of NTDs. These studies did not
provide strong conclusive evidence to support the
selection of a different subgroup distribution in
these regions. As more robust population-based
data become available from LMIC settings, this
assumption should be reviewed.
These estimates use a compartmental model
approach. We initially planned to model the overall
prevalence of NTDs using linear regression with
a random effect at the regional level, including
dummy variables for study type, method of
ascertainment, and coverage of folic acid food
fortification. However, paucity of data—in par-
ticular suitable study and national predictor and
covariate data—made this impossible.
In addition to providing a point estimate, we
sought to quantify uncertainty around the esti-
mates. Some account of uncertainty was included
at each step of the compartmental model. However,
our approach may underestimate uncertainty, as
we were unable to capture uncertainty around the
estimated number of live births in each country
or around the access-to-care assumptions. In
addition, while we assumed that the uncertainty
around the reported prevalence would follow a
Poisson distribution, this is likely to underes-
timate the uncertainty in many settings where
underascertainment is a key concern.
Comparison with previous estimates
Previous estimates published in theMarch of Dimes
Global Report on Birth Defects estimated a total
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Figure 3. Regional stacked bar chart showing the estimated prevalence for NTD birth outcomes per 10,000 live births.
of 323,900 live births with NTDs in 2001.10 These
estimates for 2015 are slightly lower, reporting
an overall birth prevalence, including eTOPFAs,
stillbirths, and live births, of 260,100. While the
detailed methods of the 2001 estimates have not
been published, the differences could be accounted
for by several factors. First, differences in esti-
mates for China and other high-burden regionsmay
be due to falling prevalence of folic acid–sensitive
NTDs, due in part to the improved nutritional and
folate status of women. Similar trends have been
observed in theUnitedKingdom,where birthpreva-
lence rates of over four per 1000 births in the 1950s
in poor, working-class populations have fallen to
the low rates reported in the present day.36 Second,
birth prevalence has fallen since 2001 in countries
that have mandated and achieved high coverage of
folic acid food fortification, as in most of North and
South America. In addition, since 2001, prenatal
detection of affected pregnancies has increased with
widespread introduction of routine ultrasound dur-
ing pregnancy, including fetal anomaly screening in
all high-income and many middle-income coun-
tries. NTDs in general and anencephaly in partic-
ular can be relatively easily detected via ultrasound
scan, and increased prenatal detection is likely to
have increased the number of women and families
seeking eTOPFAs where available, thereby reducing
the number of affected live births. The Global Bur-
den of Disease (GBD) includes NTDs as part of the
310 conditions estimated.53 This approachproduces
estimates only for live births and only uses data
frombirth defect registries (43 countries); hence, no
input data from high-burden regions (i.e., LMICs)
are included. The GBD used a Bayesian modeling
approach, seeking to adjust for underreporting and
inclusion of stillbirths in reported prevalencewithin
the modeling. The GBD reports overall prevalence
in a population at all ages andmortality only among
those born live, and hence the results are not directly
comparable with these estimates.
A potential method of triangulation for the
number of deaths is to compare these estimates
to UN estimates for cause of under-5 deaths and
reported vital registration data. We estimated that
there were around 120,000 under-5 NTD-related
deaths worldwide in 2015, compared with the UN’s
estimate of 558,554 under-5 deaths due to all con-
genital anomalies.54 However, the UN-estimated
number is recognized to underestimate these deaths
with under-capture of these outcomes in both vital
registration and verbal autopsy data owing to chal-
lenges in identifyingnonvisiblemalformations (e.g.,
congenital heart defects) and to unwillingness of
families to report birth defects because of stigma. In
2012 (the last year for which full data are available),
a total of 3054 NTD deaths from 77 countries were
reported to the WHO.55 This number of reported
NTD-related under-5 deaths is much lower than
ourmodeled estimate, but this is not altogether sur-
prising, as the highest burden countries do not have
robust death registration systems to report causes
of death to WHO, and the coverage of death reg-
istration is incomplete in many of these countries.
However, when compared to reported numbers for
North American, Latin American, and European
regions, where most countries report cause of
death, the reported number of deaths in 2012 is
comparable to our estimate for 2015 (Appendix
S10, online only).
12 Ann. N.Y. Acad. Sci. xxxx (2018) 1–16 C© 2018 The Authors. Annals of the New York Academy of Sciences
published by Wiley Periodicals Inc. on behalf of The New York Academy of Sciences.
Blencowe et al. Worldwide neural tube defects: estimates for 2015
Table 6. Estimated number of NTD-related under-5 child mortality worldwide in 2015
UN subregion
Number of
NTD-affected
birth outcomes
(UR)
Number of
NTD-affected live
births (UR)
Number of
NTD-related
under-5 deaths
NTD-related
U5MR per
1000 live
birthsa
Number of
NTD survivors
to age 5 (%)b
Australasia and Oceania 750
(530–980)
300
(170–450)
220
(100–300)
0.3
(0.2–0.5)
90
(30)
Latin America and the
Caribbean
9500
(3900–15,000)
5500
(2300–7900)
3200
(1300–4500)
0.2
(0.1–0.4)
2300
(42)
Eastern Europe and
Central Asia
4800
(3300–6400)
1600
(1000–2400)
860
(410–1300)
0.2
(0.1–0.3)
790
(49)
Sub-Saharan Africa 49,100
(27,700–83,100)
32,300
(17,400–55,300)
30,000
(15,700–49,900)
0.8
(0.5–1.4)
2300
(7)
East Asia 36,800
(20,800–53,100)
8700
(4800–13,200)
2400
(1300–3800)
0.1
(0.1–0.2)
6200
(71)
Northern Africa and
Western Asia
20,700
(11,600–30,400)
11,700
(7000–17,700)
8600
(5000–12,900)
0.6
(0.4–1.1)
3100
(26)
Europe 4200
(3900–4600)
910
(830–1020)
240
(190–320)
0.1
(0.0–0.1)
670
(74)
Southeast Asia 16,100
(7400–24,500)
11,100
(5300–17,200)
9000
(4200–13,900)
0.6
(0.3–1.1)
2100
(19)
North America 3100
(2900–3300)
860
(900–920)
220
(150–280)
0.1
(0.0–0.1)
640
(74)
Southern Asia 115,000
(81,200–158,800)
70,200
(46,200–100,000)
63,200
(38,800–87,500)
1.7
(1.1–2.4)
7000
(10)
Worldwide 260,100
(213,800–322,000)
143,200
(105,500–186,600)
117,900
(81,100–148,500)
0.8
(0.6–1.1)
25,200
(18)
UR, uncertainty range.
Note: Numbers may not add up because of rounding. Numbers in each cell are rounded to the nearest 10 for numbers <1000 and
the nearest 100 for numbers1000.
aU5MR = under-5 mortality rate, presented here per 1000 live births to allow comparison with standard reporting of under-5
mortality.3
bPercentage survival is influenced by availability of prenatal diagnosis and uptake of elective termination of pregnancy for fetal
impairment (eTOPFA). Regions with high rates of eTOPFA for anencephaly will have fewer live births with anencephaly, and
therefore fewer neonatal deaths and higher survival rates overall for NTDs.
Conclusions
Overall, results from our systematic and meta-
analyses show a high prevalence of NTDs globally,
despite many being preventable before conception
throughmandatory fortificationof staple foodswith
folic acid.This burden is largelyhidden,with around
half of all cases globally estimated to end in eTOPFAs
or stillbirths, which are often hidden and invisible
to policy makers. The impact of NTDs on mothers,
families, and society is substantial. NTDs primarily
affect women and families, confronting them with
difficult decisions, including whether to continue
with an affected pregnancy, creating psychological
burdens following stillbirth or eTOPFA, and chal-
lenging them to finance and manage the complex
care needs of an affected child.
Empirical data to inform both overall prevalence
and each step of the estimation process are currently
lacking, and these estimates therefore rely on several
assumptions. Improving surveillance of all adverse
birth outcomes, including live births, stillbirths,
and eTOPFAs, through strengthened pregnancy
and birth defect registries, especially in LMICs, is
urgently needed to improve our understanding of
total NTD prevalence. This will allow tracking of
the effects of folic acid fortification on prevent-
ing affected pregnancies and of care on improv-
ing outcomes for affected births. Much of this bur-
den is preventable before conception, and folic acid
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intervention programs should be implemented
alongside surveillance systems for achieving best
results in monitoring and control of NTD preva-
lence and associated mortality.
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